Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus

Zhang, Xuewu, Zhang, Fengchun, Wu, Donghai, Bao, Chunde, Zhu, Ping, Zhang, Xiao, Huang, Cibo, He, DongYi, Tao, Yi, Fang, Yongfei, Gu, Jieruo, Wu, Huaxiang, Sun, Lingyun, Yang, Xiuyan, Huang, Feng, Xu, Huji, Zhao, Dongbao, Zhang, Miaojia, Zheng, Yi and Li, Zhanguo (2013) Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus. International Journal of Rheumatic Diseases, 16 4: 408-412. doi:10.1111/1756-185X.12125


Author Zhang, Xuewu
Zhang, Fengchun
Wu, Donghai
Bao, Chunde
Zhu, Ping
Zhang, Xiao
Huang, Cibo
He, DongYi
Tao, Yi
Fang, Yongfei
Gu, Jieruo
Wu, Huaxiang
Sun, Lingyun
Yang, Xiuyan
Huang, Feng
Xu, Huji
Zhao, Dongbao
Zhang, Miaojia
Zheng, Yi
Li, Zhanguo
Title Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus
Journal name International Journal of Rheumatic Diseases   Check publisher's open access policy
ISSN 1756-1841
1756-185X
Publication date 2013-08
Year available 2013
Sub-type Article (original research)
DOI 10.1111/1756-185X.12125
Open Access Status DOI
Volume 16
Issue 4
Start page 408
End page 412
Total pages 5
Place of publication Richmond, VIC Australia
Publisher Wiley-Blackwell Publishing Asia
Collection year 2013
Language eng
Formatted abstract
Objective
To evaluate the safety of tumor necrosis factor-α (TNF-α) monoclonal antibody (infliximab) therapy in patients with rheumatoid arthritis (RA) and previous exposure to hepatitis B virus (HBV) who had normal liver function.

Methods
This is a retrospective study from a 26-week, prospective, multicenter trial in 234 patients with RA who received infusions of infliximab (3 mg/kg at week 0, 2, 6, 14 and 22). The medical records of these patients were reviewed, including the information on disease duration, laboratory tests and HBV markers. The data on liver function during the study was analyzed, as well as comparison between patients with previous exposure to HBV and patients without such exposure.

Results
Forty-one patients with previous exposure to HBV were HBsAg(-). Forty patients had normal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and only one patient with positive anti-HBc showed an elevated ALT level before administration of infliximab, and had a further increase of ALT level at week 14, but decreased thereafter. The average ALT and AST levels rose slightly during the treatment but remained in normal range and the differences were insignificant compared with baseline. There was no statistically significant difference in the incidence of liver function abnormalities during the treatment of infliximab between the patients with previous exposure to HBV and those without such exposure.

Conclusion
In patients with RA and previous exposure to HBV but with a negative HBsAg and normal liver function at baseline, liver function abnormalities were not observed during infliximab treatment.
Keyword HBV infection
Infection
Infliximab
Rheumatoid arthritis
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ
Additional Notes ERA

Document type: Journal Article
Sub-type: Article (original research)
Collection: Queensland Brain Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 11 Sep 2014, 09:37:42 EST by Debra McMurtrie on behalf of Queensland Brain Institute